Surgical Robotics Market to Reach US$15.25 Billion by 2033
The global surgical robotics market is projected to grow from US$5.84 billion in 2024 to US$15.25 billion by 2033, exhibiting an 11.3% CAGR, driven by increased adoption of robotic-assisted systems for enhanced precision and patient outcomes. North America currently leads the market with a 51% share due to advanced healthcare infrastructure and strong presence of key players, while major drivers include demand for minimally invasive surgeries, rising chronic disease prevalence, and technological advancements like AI integration. Key players in this evolving market include Intuitive Surgical, Stryker Corporation, and CMR Surgical.
Intuitive Surgical, Inc. (ISRG) announces the completion of its acquisition of the da Vinci and Ion distribution business
Intuitive Surgical, Inc. (ISRG) announced the successful acquisition of the da Vinci and Ion distribution business. This strategic move aims to integrate key distribution channels directly under Intuitive Surgical's control, streamlining operations and enhancing market reach for its robotic surgical systems. The acquisition is expected to bolster the company's growth trajectory and optimize customer service.
Restore Robotics Gains FDA OK to Remanufacture 2 More da Vinci Xi Robotic Instruments
Restore Robotics has received additional FDA 510(k) clearances for remanufacturing two more da Vinci Xi robotic surgical instruments, expanding its portfolio. This achievement reinforces the company's commitment to providing cost-effective, high-quality, and sustainable alternatives to new robotic instruments for hospitals and surgery centers. The collaboration with Encore Medical Device Repair will facilitate broader distribution, helping healthcare providers reduce costs and promote environmental stewardship.
Evercore ISI Adjusts PT on Intuitive Surgical to $480 From $550, Maintains In Line Rating
Evercore ISI has adjusted its price target for Intuitive Surgical (NASDAQ:ISRG) from $550 to $480, while maintaining an "In Line" rating on the stock. This revision reflects a change in the firm's outlook on the company.
Rathbones Group PLC Trims Position in Intuitive Surgical, Inc. $ISRG
Rathbones Group PLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.7% in the fourth quarter, selling 16,919 shares and holding 445,373 shares valued at $252.24 million. Other hedge funds also adjusted their positions in ISRG, while institutional investors collectively own 83.64% of the stock. Analysts have a "Moderate Buy" consensus rating with an average target price of $614.95, and company insiders have sold shares totaling over $17 million in the last ninety days.
2,407 Shares in Intuitive Surgical, Inc. $ISRG Acquired by Buffalo Business & Estate Services Ltd.
Buffalo Business & Estate Services Ltd. recently acquired 2,407 shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in Q4, a stake valued at approximately $1.36 million. Intuitive Surgical exceeded Q4 expectations with an EPS of $2.53 and revenue of $2.87 billion, representing an 18.8% year-over-year increase. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $614.95, and some firms have raised their price targets for the medical equipment provider.
Intuitive Surgical, Inc. $ISRG Shares Sold by GraniteShares Advisors LLC
GraniteShares Advisors LLC reduced its stake in Intuitive Surgical (ISRG) by over 80% in Q4, selling 2,351 shares, while other institutional investors like Independence Bank of Kentucky and RPG Investment Advisory LLC increased their holdings. Insider selling also occurred, with Director Gary S. Guthart selling a significant number of shares. Despite these sales, analysts maintain a "Moderate Buy" consensus rating with a target price of $614.95 for ISRG.
RPG Investment Advisory LLC Purchases 6,945 Shares of Intuitive Surgical, Inc. $ISRG
RPG Investment Advisory LLC increased its stake in Intuitive Surgical, Inc. by 20.5% in Q4, acquiring 6,945 additional shares to hold a total of 40,752 shares valued at $23.08 million. This makes Intuitive Surgical the fund's 11th largest holding. The medical equipment provider recently reported strong quarterly earnings, beating analyst estimates with $2.53 EPS and $2.87 billion in revenue, representing an 18.8% year-over-year increase.
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in PROCEPT BioRobotics Corporation ($PRCT) during Q4, acquiring an additional 49,457 shares to hold a total of 84,294 shares valued at $2.65 million. Despite this institutional buying and overall insider net purchases, the company reported a Q4 earnings miss and revenue below expectations, leading to a mixed analyst consensus of "Hold" with a target price of $40.82. The article highlights other institutional movements and recent insider sales by two EVPs, even as insiders were net buyers over the quarter.
Intuitive Surgical Inc. (ISRG): Firm Releases Updates For da Vinci 5
Intuitive Surgical (ISRG) has released significant updates for its da Vinci 5 surgical system, including software enhancements aimed at improving precision and efficiency. These updates strengthen the system's capabilities, potentially leading to better patient outcomes and increased surgeon adoption. The improvements reflect Intuitive Surgical's ongoing commitment to advancing robotic-assisted surgery technology.
SteelPeak Wealth LLC Sells 31,864 Shares of Intuitive Surgical, Inc. $ISRG
SteelPeak Wealth LLC significantly reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by selling 31,864 shares in Q4, though institutional investors still hold a large percentage of the stock. Despite insider selling, several large funds materially increased their positions, and Intuitive Surgical beat quarterly earnings and revenue estimates. Analysts maintain a "Moderate Buy" rating with an average price target of $614.95, indicating optimism for the medical equipment provider's future performance.
Quintet Private Bank Europe S.A. Sells 12,513 Shares of Intuitive Surgical, Inc. $ISRG
Quintet Private Bank Europe S.A. reduced its stake in Intuitive Surgical (NASDAQ:ISRG) by 21.5% in the fourth quarter, selling 12,513 shares. Despite this reduction, Intuitive Surgical remains a significant holding for the bank, comprising 1.5% of its portfolio. Other institutional investors like SteelPeak Wealth LLC and Atlantic Union Bankshares Corp increased their holdings in the medical equipment provider during the same period.
Rambus CEO Sells Over $470K in Shares
Rambus CEO Luc Seraphin sold 5,426 shares of the company's stock for over $470,000 on April 2nd, 2026, as part of a pre-arranged trading plan, reducing his ownership by 1.55%. This follows a previous sale in March and leaves him with approximately $29.96 million in shares. While insider selling can raise concerns, the company attributes this transaction to a planned strategy, assuring that it does not indicate broader issues for the semiconductor technology licensing firm.
Intuitive Surgical, Inc. stock: Robotic surgery leader or overvalued play?
This article analyzes Intuitive Surgical (ISRG), a leader in robotic surgery with its da Vinci systems, assessing whether its market dominance justifies its premium valuation. It highlights the company's strong recurring revenue model and expansion into various surgical fields, while also cautioning investors about market volatility, competition from Medtronic, and potential risks like reimbursement pressures and cybersecurity concerns. The piece suggests that ISRG could be a good long-term investment for North American investors who believe in the growth of robotic surgery and can tolerate market swings.
Intuitive Surgical, Inc. stock: Robotic surgery leader or overvalued play?
Intuitive Surgical, Inc. is a leader in robotic surgery with its da Vinci Surgical System, facing market volatility despite long-term growth. The company benefits from a "razor-and-blade" revenue model and expanding surgical applications, but also faces risks from competition, reimbursement pressures, and high valuation. Investors should consider the stock's growth potential versus its premium price and economic headwinds.
Restore Robotics cleared to remanufacture 2 more da Vinci Xi instruments
Restore Robotics has received 510(k) clearance from the FDA for two additional Intuitive Surgical da Vinci Xi instruments: the permanent cautery hook and spatula. This brings Restore's total FDA clearances for da Vinci instruments to four, significantly expanding its capabilities in remanufacturing these robotic surgical tools. The company aims to provide hospitals and surgery centers with cost-effective, high-quality, and sustainable alternatives to new instruments, partnering with Encore Medical Device Repair for distribution.
Axonics Inc stock: Why this medtech innovator is worth watching now
Axonics Inc is presented as a compelling investment in the medtech sector, specifically for its innovative sacral neuromodulation system treating bladder and bowel disorders. The article highlights the company's competitive edge through advanced technology, patient-centric design, and a growing market presence in North America. It emphasizes Axonics' strong financial health, consistent revenue growth, and favorable analyst perspectives, while also outlining potential risks for investors to monitor.
At US$452, Is Intuitive Surgical, Inc. (NASDAQ:ISRG) Worth Looking At Closely?
This article examines Intuitive Surgical, Inc. (NASDAQ:ISRG) at its current stock price of US$452. It will likely delve into valuation metrics to determine if the company presents a compelling investment opportunity. The analysis aims to help potential investors decide if closely evaluating ISRG is worthwhile.
Stereotaxis (NYSE: STXS) details 2026 meeting, director elections and say-on-pay
Stereotaxis, Inc. will hold its 2026 Annual Meeting on May 14, 2026, where shareholders will vote on the election of three Class I directors, the ratification of Ernst & Young LLP as the 2026 auditor, and an advisory "say-on-pay" resolution for executive compensation. The proxy statement details the company's governance structure, director independence, and executive compensation philosophy, which heavily weights long-term equity incentives tied to performance. Key figures regarding outstanding shares, voting power, and executive salaries, including the CEO's $60,000 base salary, are also provided for shareholder review.
ISRG stock $452.07 pre-market (Intuitive Surgical, NASDAQ) 03 Apr 2026: AI robotics test
Intuitive Surgical (ISRG) saw its stock open pre-market at $452.07, down 2.67% on April 3, 2026, despite strong recent earnings, as traders digest AI-driven robotics demand and evaluate its premium valuation. Meyka AI maintains a "BUY" suggestion with a 12-month target of $585.45, highlighting the company's strong fundamentals and growth potential in AI-enabled surgical robotics, but acknowledges execution and sentiment risks. Investors are advised to monitor procedure volumes and instrument attach rates to validate growth assumptions.
Aberdeen Group plc Cuts Position in Intuitive Surgical, Inc. $ISRG
Aberdeen Group plc reduced its stake in Intuitive Surgical, Inc. (ISRG) by 2.0% in Q4, selling 7,568 shares to hold 380,508 shares valued at $215.5 million. This comes amidst significant insider selling of 32,943 shares worth $17.28 million over the last 90 days. Despite the share reduction, Intuitive Surgical reported strong Q4 earnings, beating estimates with $2.53 EPS and $2.87 billion in revenue, and analysts maintain a "Moderate Buy" rating with an average target price of $614.95.
Intuitive Surgical, Inc. Stock: Leader in Robotic Surgery Faces Evolving Healthcare Landscape
Intuitive Surgical, Inc. (ISIN: US46120E6023) is a dominant force in robotic-assisted surgery with its da Vinci systems, generating steady growth through a "razor-and-blade" business model and continuous technological innovation. North American investors are drawn to its strong market position, recurring revenue streams, and potential for expansion in an evolving healthcare landscape, despite risks from competitive intensification and regulatory scrutiny. The article highlights the company's core business model, technological edge, and market dominance, advising investors to monitor procedure growth and innovation.
Intuitive Surgical, Inc. Stock: Leader in Robotic-Assisted Surgery Faces Growth Challenges Amid Mark
Intuitive Surgical, Inc. (ISRG) dominates the robotic-assisted surgery market with its da Vinci systems, known for precision and reduced patient recovery times. Despite its strong market position and robust procedure growth, the company faces challenges from increasing competition from companies like Medtronic and Johnson & Johnson, as well as risks associated with regulatory scrutiny and potential economic headwinds impacting elective surgeries. Investors are drawn to ISRG for its innovative technology and growth potential, but are advised to monitor competitive developments and the adoption rates of new platforms.
Intuitive Surgical Inc. stock underperforms Thursday when compared to competitors
Shares of Intuitive Surgical Inc. (ISRG) fell by 2.67% on Thursday, closing at $452.07. This underperformance occurred during a mixed trading session where the S&P 500 Index rose slightly and the Dow Jones Industrial Average experienced a small decline. The stock's drop ended a three-day winning streak.
Intuitive Surgical, Inc. Stock: Leader in Robotic-Assisted Surgery Faces Growth Challenges Amid Mark
Intuitive Surgical (ISRG) dominates the robotic-assisted surgery market with its da Vinci systems, offering precision and efficiency in medical procedures. Despite its strong market position and robust procedural growth, the company faces challenges from increasing competition and relies on continued execution on new platforms for sustained growth. North American investors view ISRG as a compelling long-term investment due to its alignment with demographic trends and innovative technology, though risks like regulatory scrutiny and economic headwinds exist.
Intuitive Surgical Drops 2.9%: Exploring the Reasons for the Steep Decline Amid Growing Bearish Sentiment
Intuitive Surgical (ISRG) shares experienced a nearly 3% drop, hitting a new 52-week low due to strong bearish sentiment highlighted by technical indicators and options trading activity. Despite a mixed performance in the Healthcare Equipment sector, ISRG's decline is attributed to internal factors and significant short-term bearish options plays. While historical data suggests a tendency for recovery after steep drops, key support levels need monitoring as bearish momentum continues.
Intuitive Surgical Under Pressure in China: Can It Defend Its Position?
Intuitive Surgical (ISRG) is facing significant competitive and policy-driven challenges in China, with local robotic suppliers gaining an advantage through provincial tenders. This has led to declining tender win ratios and increased price competition for ISRG. While the company is implementing strategies like local manufacturing and leveraging its broader ecosystem, China is expected to become a more competitive and lower-margin market.
Intuitive Surgical Under Pressure in China: Can It Defend Its Position?
Intuitive Surgical (ISRG) is facing increasing competitive and policy-driven pressures in China, with local rivals gaining ground and tenders favoring domestic suppliers, leading to declining win ratios and pricing pressure. The company is responding by manufacturing locally and leveraging its ecosystem, though the market may become lower-margin. Competitors like Globus Medical (GMED) and Stereotaxis (STXS) face comparatively lower specific risks in China but still navigate global pricing challenges.
At Harvard gala, QT Imaging CEO pushes earlier breast cancer detection
QT Imaging Holdings, Inc. CEO Dr. Raluca Dinu participated in the inaugural Shiftmakers Gala at Harvard University, highlighting the importance of early breast cancer detection. Dinu emphasized that their radiation-free imaging technology addresses the challenge of dense breast tissue, which often makes mammography alone insufficient for many women. The event, supported by Gloria Steinem, focused on women driving change, and QT Imaging's work will be featured in The Shift to further promote awareness.
HF Advisory Group LLC Has $6.64 Million Position in Becton, Dickinson and Company $BDX
HF Advisory Group LLC significantly increased its stake in Becton, Dickinson and Company (BDX) by 559.3% in Q4, holding 34,230 shares valued at $6.643 million. BDX surpassed Q4 earnings expectations with $2.91 EPS and $5.25 billion revenue, and analysts currently rate the stock as "Hold" with a target price of $191.62. The company also announced a quarterly dividend of $1.05 per share and a $10 million share repurchase plan.
Intuitive Surgical Stock Near Crucial Support – Buy Signal?
Intuitive Surgical (ISRG) stock is currently trading within a crucial support zone, having bounced significantly from these levels multiple times in the past. The article suggests a rebound is likely due to robust sector growth, strong Q4 2025 performance, and a growing robotic surgery market. Despite competitive pressures and an elevated valuation, analyst targets imply significant upside, while technical indicators like an oversold RSI also support a potential bounce.
Intuitive Surgical, Inc. Stock: Leader in Robotic Surgery Faces Valuation Scrutiny Amid Analyst Shif
Intuitive Surgical (ISRG) dominates the robotic-assisted surgery market with its da Vinci systems, exhibiting strong revenue and procedure growth. Despite its market leadership and recurring revenue model, the stock faces valuation scrutiny demonstrated by recent analyst downgrades and high price-to-earnings ratios. North American investors are weighing the company's growth potential against these valuation concerns and competitive pressures.
Top Analyst Reports for American Express, Intuitive Surgical & Shopify
Zacks Research Daily highlighted top analyst insights on 16 leading companies, focusing on American Express (AXP), Intuitive Surgical (ISRG), Shopify Inc. (SHOP), and Utah Medical Products, Inc. (UTMD). The reports detail each company's recent performance, growth drivers, and potential challenges, with American Express showing growth despite high costs, Intuitive Surgical excelling with its da Vinci system, and Shopify expanding its merchant base. The analysis also covers Utah Medical Products' strong balance sheet, along with brief mentions of other companies like Petróleo Brasileiro S.A. - Petrobras, Southern Copper Corp., and Agnico Eagle Mines Ltd.
Intuitive Surgical, Inc. (ISRG) Maintains Edge Despite Security Breach
Intuitive Surgical Inc. (ISRG) recently experienced a phishing attack that exposed some customer and employee data, though its critical da Vinci and Ion robotic systems were unaffected due to network segmentation. The company emphasized that its operations and customer support remain fully functional and that its training systems are a key competitive advantage that competitors like Johnson & Johnson and Medtronic struggle to replicate. Despite the security incident and potential risks, Intuitive Surgical maintains its leadership in robotic-assisted surgery with a global presence and millions of procedures performed.
The Intuitive da Vinci 5’s 10,000x computing leap: Here’s what it means
The da Vinci 5, Intuitive's latest robotic surgery system, boasts 10,000 times the computing power of its predecessor, the da Vinci Xi, enabling advanced capabilities like force sensing and enhanced post-procedure analytics. This technological leap, developed in partnership with NVIDIA, facilitates remote telepresence and allows surgeons to meticulously review cases using objective data. Dr. Douglas Stoddard highlighted how the new system's Case Insights platform translates raw surgical data into navigable performance analytics, revolutionizing post-surgical debriefing and training.
A surgeon and Intuitive exec explain what da Vinci 5's 10,000x computing leap actually looks like, inside and outside the OR
The da Vinci 5, Intuitive's latest surgical system, offers a 10,000x computing power increase over its predecessor, enabling new capabilities like force sensing and advanced data analytics. Surgeons like Douglas Stoddard are using features like telepresence and Case Insights to review procedures, quantify surgical movements, and collaborate globally, moving surgery from an art to a more data-driven science. This technological leap aims to reduce variability in surgical outcomes, broaden access to surgical expertise, and accelerate discovery in the field.
Intuitive Surgical, Inc. Stock: Leader in Robotic Surgery Faces Valuation Scrutiny Amid Analyst Shifts
Intuitive Surgical, Inc. (ISIN: US46120E6023), a leader in robotic-assisted surgery, is facing valuation scrutiny despite strong procedure growth. Recent analyst downgrades and high multiples signal caution for investors, though institutional activity shows continued confidence in the long-term demand for robotics. The company's unique "razor-and-blade" business model ensures stable recurring revenue, positioning it well within the high-growth medtech sector, but investors must monitor potential risks like valuation and competitive pressures.
WST Expands Dublin Facility to Boost Injectable Therapy Capacity
West Pharmaceutical Services (WST) has expanded its Dublin facility with a new 165,000 square foot building to meet the rising global demand for high-volume injectable therapies, especially for chronic diseases like diabetes and obesity. This expansion enhances WST's contract manufacturing capabilities under its West Vantage platform, offering end-to-end development support and strengthening its position in the injectable drug delivery market. Following this news and strong Q4 2025 results, the company expects sustained growth and improved long-term value.
Reasons to Retain Abbott Stock in Your Portfolio Now
Abbott Laboratories (ABT) is expected to see growth driven by strong sales recovery in its Nutrition business, particularly the Ensure brand, and continued robust adoption of its FreeStyle Libre CGM system in Diabetes Care. However, the company faces headwinds from currency fluctuations and a challenging macroeconomic environment. Despite these challenges, Abbott's strategic initiatives in product innovation and expanded market reach for its Diabetes Care franchise position it for future growth.
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
Johnson & Johnson has transformed from a consumer-facing conglomerate into a "pure-play" healthcare powerhouse, focusing solely on Innovative Medicine and MedTech after divesting its consumer health business. Under CEO Joaquin Duato, the company is prioritizing high-margin medical breakthroughs, aggressive M&A, and digital integration. Despite legal challenges and patent cliffs, J&J maintains a strong financial position, robust growth prospects, and consistent investor returns, with a strategic focus on robotic surgery and pharmaceutical pipeline acceleration.
Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC reduced its stake in Zimmer Biomet Holdings, Inc. by 31.5% in the fourth quarter, selling 15,033 shares. Despite this, Zimmer Biomet reported strong Q results, topping revenue and EPS estimates, and declared a quarterly dividend. Other institutional investors, however, increased their holdings in the medical equipment provider.
Nisa Investment Advisors LLC Acquires 3,370 Shares of Intuitive Surgical, Inc. $ISRG
Nisa Investment Advisors LLC increased its stake in Intuitive Surgical, Inc. by 3.2% in the fourth quarter, purchasing an additional 3,370 shares to hold a total of 109,861 shares valued at $62.22 million. Other institutional investors like Rakuten, Assenagon, Amundi, Sands Capital, and Victory Capital also significantly boosted their positions. Despite insider selling, analysts maintain a "Moderate Buy" consensus rating with an average target price of $614.95, following the company's recent earnings beat.
Zacks Research Downgrades Intuitive Surgical (NASDAQ:ISRG) to Hold
Zacks Research downgraded Intuitive Surgical (NASDAQ:ISRG) from a "strong-buy" to a "hold" rating due to recent insider selling and a technical pullback, despite strong Q4 2025 earnings which beat analyst estimates. The company's fundamentals remain solid, with revenue up 18.8% year-over-year and an EPS of $2.53 against an estimated $2.27. Analysts collectively rate ISRG a "Moderate Buy" with an average price target of $614.95.
Heirloom Wealth Management Buys 16,650 Shares of Intuitive Surgical, Inc. $ISRG
Heirloom Wealth Management significantly increased its holdings in Intuitive Surgical, Inc. (ISRG) by 3,700% in the fourth quarter, purchasing an additional 16,650 shares to now own 17,100 shares valued at $9.685 million. This makes ISRG the 17th largest holding for the fund. The article notes positive analyst sentiment with a "Moderate Buy" rating and an average price target of $614.95, following Intuitive Surgical's strong quarterly earnings beat with $2.53 EPS and $2.87 billion in revenue.
Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Microbot Medical Inc. (NASDAQ:MBOT) has received a consensus "Moderate Buy" rating from five brokerages, with an average 12-month price target of $7.50. Institutional ownership in the company is growing, now accounting for 16.3% of shares, with several funds increasing their positions. The biotechnology company recently reported a quarterly EPS of ($0.04), beating analyst estimates.
ISRG Intuitive Surgical NASDAQ pre-market 01 Apr 2026: $460.99 AI outlook
Intuitive Surgical (ISRG) is trading at $460.99 pre-market on April 1, 2026, supported by strong fundamentals and AI-driven robotics. Meyka AI rates ISRG with a B+ (BUY) and projects a yearly target of $585.45, implying a 27% upside, despite current technical weakness and a premium valuation. Investors are advised to watch the upcoming April 21, 2026 earnings report for further cues on system placements and consumable growth.
Intuitive Surgical, Inc. (ISRG) rises but trails market: What investors should know
Intuitive Surgical (ISRG) experienced a 1.25% gain, closing at $372.44, yet it underperformed the S&P 500's daily gain of 1.48%. The stock has seen a 2.59% increase over the past month, contrasting with the Medical sector's 3.39% loss and the S&P's 2.9% gain. Upcoming earnings in late April will be key for investors assessing its short-term performance.
Exoskeleton Rehabilitation Market Overview: Major Segments, Strategic Developments, and Leading Companies
The exoskeleton rehabilitation market is projected to reach $2.91 billion by 2030, growing at a CAGR of 17.4%, driven by technological advancements, home-based rehabilitation, AI-guided therapy, and an aging population. Key companies like Ottobock SE and Co KGaA, Fourier Intelligence, and Cyberdyne Inc. are leading this expansion, with significant strategic moves such as Bioness Medical Inc.'s acquisition of Harmonic Bionics Inc. The market is segmented by product type (lower, upper, full-body exoskeletons), mobility (mobile, stationary), application (neurological, orthopedic, spinal cord injury, stroke), and end-user (hospitals, rehabilitation centers).
Intuitive Surgical, Inc. (ISRG) Moves Up Yet Lags Behind the Market: Key Information for Investors
Intuitive Surgical (ISRG) recently saw a 1.81% stock increase but lagged behind major indices like the S&P 500. Over the past month, ISRG shares declined by 8.76%, though this was less severe than the overall Medical sector. Investors are anticipating robust Q1 earnings with projected EPS of $2.08 and revenue of $2.61 billion, and analysts generally hold a "Hold" rating for the stock.
Mn Services Vermogensbeheer Boosts Stake in Intuitive Surgical
Mn Services Vermogensbeheer B.V. increased its stake in Intuitive Surgical (NASDAQ: ISRG) by 1.9% during the fourth quarter, signaling confidence in the medical technology company's robotic surgical systems. The institutional investor now owns 138,778 shares valued at $78,598,000. This move highlights Intuitive Surgical's strong market position and long-term growth potential in robotic-assisted surgery.
